Diagnostics

Chronic fatigue, anxiety, and burnout are surging. A new wave of data-driven, integrative medicine claims to have the answer, moving beyond symptoms to the root cause.

With a history of beating expectations and a flurry of strategic moves, Quest Diagnostics' July 23rd earnings report is a key vital sign for the entire diagnostics sector.

New data on ersodetug reveals a calculated strategy to conquer hyperinsulinism, balancing patient hope with the harsh realities of the biotech market.

With $1.25M in new funding, Avricore Health isn't just raising capital; it's accelerating a strategic pivot to the lucrative UK market for its HealthTab platform.

Adaptive Biotechnologies' sophisticated convertible note offering isn't just about capital; it's a strategic de-risking of its finances to accelerate its fight against cancer.

A new study validates iMDx's precision diagnostic tech, setting the stage for a strategic assault on the centralized lab model for organ rejection monitoring.

A landmark court ruling forces a recall of Siemens' latest mammography tech, handing Hologic a major victory and sending shockwaves through Europe's MedTech.

As a rare Ebola strain rages in a DRC warzone, the G7 pledges massive aid. But with fragile peace deals and no proven cure, is it enough to stop a global crisis?

A forgotten corner of oncology is set for a 14.2% CAGR. A new wave of drugs for chemo-induced neuropathy signals a major market realignment.

The PD-L1 biomarker testing market is set to double by 2036, fueling a revolution in cancer care. But as innovation races ahead, who gets left behind?

Ice Cube's BIG3 league and the PCF are deploying a new playbook, using basketball's cultural power to bring life-saving cancer screenings directly to Black men.

Komodo Health restructures its C-suite, signaling a major shift in healthcare. It's no longer about AI hype; it's about enterprise-scale dominance.

A record $1.15M campaign for blood cancer reveals a new playbook where executive influence, not just corporate checks, drives profound social impact.

A small med-tech firm is betting its future on fingerprint sweat. Can its novel drug test pass the FDA's rigorous trials and disrupt a billion-dollar market?

In a strategic pivot, GeneDx brings in former Quest and Thermo Fisher exec Mark Gardner to translate its genomic leadership into commercial dominance.

Quoin Pharma's new data for a rare skin disease shows life-changing results in children, offering hope for families. What do the numbers really mean?

A new corporate alliance is targeting veteran lung disease. It’s more than a webinar; it’s a strategic response to the PACT Act’s seismic shift.

BioAge Labs starts a Phase 2 trial for BGE-102, an oral drug targeting inflammation to reduce heart risk, a strategy that could redefine cardiovascular care.

Quest's latest responsibility report claims leadership in ESG. We analyze its community investments, workforce strategy, and tech governance to gauge its impact.

A new pact between Canada’s CASTL and Ireland’s NIBRT, backed by top leaders, aims to solve a critical talent shortage and secure the global pharma supply chain.